About: A review of cardiac manifestations and predictors of outcome in patients with COVID

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: A review of cardiac manifestations and predictors of outcome in patients with COVID – 19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	A review of cardiac manifestations and predictors of outcome in patients with COVID – 19
Creator	Lal, Amos George, Anna Kamal, Kant Mishra, Ajay George, Amos Kant Sahu, Kamal Lal, Sahu, Anna
Source	Elsevier; Medline; PMC
abstract	Abstract Coronavirus disease (COVID-19) pandemic has so far involved 184 countries and more than 2.79 million patients worldwide. Over the past three months, it has attributed to more than 196, 000 deaths, with more than 50, 000 deaths in the United States alone. Pulmonary manifestations are predominant and have been well identified. Cardiac involvement is also common. Acute cardiac injury, the most common cardiac manifestation of this disease can be seen in patients even without prior cardiac comorbidities. Established cardiovascular risk factors such as diabetes mellitus, hypertension, and coronary artery disease predispose to cardiac injury, the severity of illness and mortality. Non-ischemic myocardial injury secondary to cytokine storm is thought to be the predominant mechanism of acute cardiac injury associated with COVID-19. Multiple mechanisms and processes contribute to cardiac injury resulting in a poor outcome. Some of these are not clearly understood. Clinical and diagnostic details of cardiovascular involvement in these patients are mostly limited to biochemical markers. Multiple therapeutic agents have been tried with questionable efficacy and without clinical evidence. Interactions of comorbidities, cardiovascular drugs, the cardiac effect of therapeutic agents on the illness continue to be under investigation. With an increasing number of patients, newer promising therapies, and ongoing clinical trials, the exact mechanisms and extent to which these risk factors contribute to outcomes will be clearer in the future.
has issue date	2020-05-03(xsd:dateTime)
bibo:doi	10.1016/j.hrtlng.2020.04.019
bibo:pmid	32593418
has license	els-covid
sha1sum (hex)	37994068cfd81abe2fd2970451abcdf859fb715c
schema:url	https://doi.org/10.1016/j.hrtlng.2020.04.019
resource representing a document's title	A review of cardiac manifestations and predictors of outcome in patients with COVID – 19
has PubMed Central identifier	PMC7196397
has PubMed identifier	32593418
schema:publication	Heart Lung
resource representing a document's body	covid:37994068cfd81abe2fd2970451abcdf859fb715c#body_text
is schema:about of	named entity 'patients' named entity 'COVID' named entity 'Cardiac enzymes' named entity 'atrial fibrillation' named entity 'United States' named entity 'ICU' named entity 'Angiotensin' named entity 'EKG' named entity 'transthoracic' named entity 'chest x-rays' named entity 'troponin' named entity 'coronavirus infection' named entity 'fulminant' named entity 'prognosis' named entity 'troponin' named entity 'cardiovascular' named entity 'azithromycin' named entity 'hypokinesis' named entity 'COVID -19' named entity 'ferritin' named entity 'EKG' named entity 'COVID' named entity 'coronary artery disease' named entity 'ARDS' named entity 'sinus tachycardia' named entity 'pulmonary parenchymal' named entity 'azithromycin' named entity 'Systemic inflammation' named entity 'clinical outcome' named entity 'IVC' named entity 'CPK' named entity 'heart failure' named entity 'cTnI' named entity 'myocarditis' named entity 'ventricular rate' named entity 'multi-organ failure' named entity 'cardiac biomarkers' named entity 'gene expression' named entity 'stenosis' named entity 'COVID' named entity 'troponin' named entity 'hydroxychloroquine' named entity 'shortness of breath' named entity 'organ dysfunction' named entity 'electrocardiography' named entity 'prothrombotic' named entity 'hypertension' named entity 'cardiac myocytes' named entity 'ligand' named entity 'pericardial effusion' named entity 'IL-6 receptor' named entity 'cardiovascular risk factors' named entity 'infection' named entity 'coronary artery disease' named entity 'echocardiography' named entity 'left ventricular ejection fraction' named entity 'non-specific' named entity 'smooth muscle cells' named entity 'cardiovascular' named entity 'ACE 2' named entity 'IL-7' named entity 'cardiovascular' named entity 'cytokine storm' named entity 'ACE 2' named entity 'ejection fraction' named entity 'pericardial effusion' named entity 'hypertension' named entity 'creatinine kinase' named entity 'myocarditis' named entity 'comorbidities' named entity 'heart failure' named entity 'leukocytes' named entity 'coronary artery disease' named entity 'ischemic heart disease'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software